Review article: the complexity of drug development for irritable bowel syndrome.
Drug development for functional gastrointestinal disorders is complex. These conditions involve central and peripheral physiological changes, together with psychological factors. Methodological problems have included a poor appreciation of the physiological and psychological correlates of patients' symptoms, a lack of animal models of proven relevance, and safety issues. Government, patient pressure groups and the Internet can also influence a drug's success. Most recent interest has focused on the serotonin (5-HT) modifying drugs. Cisapride has been withdrawn in some countries because of concerns related to QT prolongation and cardiac arrhythmias. The 5-HT3 antagonists, developed to modify visceral sensation, have caused constipation; alosetron, also withdrawn, caused ischaemic colitis. The 5-HT4 agonists induce peristalsis; tegaserod and prucalopride, both delayed in their development due to issues of safety and efficacy, benefit patients with 'constipation-predominant' irritable bowel syndrome or idiopathic constipation. 5-HT1 agonists improve impaired gastric accommodation and symptoms in patients with functional dyspepsia. Antidepressants also affect serotonin metabolism. Previous examples of success in this area involved drugs targeted at peripheral receptors mediating motor function or secretion. Modification of sensory function is a much more challenging objective. The experience with serotonin modifying drugs has been mixed, and some important lessons are there to be learnt.
Kamm
M A
MA
Physiology Unit, St Mark's Hospital, London, UK. kamm@ic.ac.uk
D000928:Antidepressive Agents / Q000627:therapeutic use; D003109:Colonic Diseases, Functional / Q000188:drug therapy*; D015195:Drug Design; D006801:Humans; D011358:Product Surveillance, Postmarketing; D018490:Serotonin Agents / Q000009:adverse effects / Q000627:therapeutic use*
D000928:Antidepressive Agents; D018490:Serotonin Agents